I. SUMMARY OF THE EXEMPTION DOCUMENT

1.1 Introduction and Warnings

BioNTech SE, a European company (*Societas Europaea, SE*) with its registered seat in Mainz, Federal Republic of Germany ("**Germany**"), and its business address at An der Goldgrube 12, 55131 Mainz, Germany, legal entity identifier ("**LEI**") 894500UZJ5LG1F8J1U58 (the "**Company**", and together with its consolidated subsidiaries, "**BioNTech**", the "**BioNTech Group**", the "**Group**", "**we**", "**us**" and "**our**") has entered into a purchase agreement, dated as of June 12, 2025, (the "**Purchase Agreement**") by and between BioNTech SE and CureVac N.V. Pursuant to the Purchase Agreement, BioNTech SE will commence an offer (the "**Offer**") to the shareholders of CureVac N.V. ("**CureVac**", and each of its shareholders, a "**CureVac Shareholder**") to acquire all issued ordinary shares with a par value of €0.12 per share of CureVac (Nasdaq Trading Symbol: CVAC) (the "**CureVac Shares**") tendered by CureVac Shareholders. In exchange for each tendered CureVac Share, the Company offers a number of newly registered American Depositary Shares of the Company (the "**Offer ADSs**") determined by multiplying the number of tendered CureVac Shares with the Exchange Ratio, taken to five decimals. The "**Exchange Ratio**" is determined by dividing $5.4641 by the BioNTech ADS VWAP. The "**BioNTech ADS VWAP**" in turn is determined as the volume-weighted average of the price per BioNTech ADS (as defined below), taken to four decimal places, over the period of ten consecutive trading days ending on, and including, the fifth trading day immediately preceding the time on which the initial Offer expires (as it may be extended), and is subject to the following collar adjustment: In the event the BioNTech ADS VWAP is greater than or equal to $126.55, the Exchange Ratio will be 0.04318 and in the event the BioNTech ADS VWAP is less than or equal to $84.37, the Exchange Ratio will be 0.06476. The resulting number of Offer ADSs to be received is referred to as the "**Offer Consideration**". The Company will only deliver whole Offer ADSs. For any fractional Offer ADSs, the tendering CureVac Shareholder will instead receive an amount in cash, without interest and less any applicable tax withholding equal to the product of (i) the fractional Offer ADS interest such shareholder otherwise would be entitled to and (ii) the BioNTech ADS VWAP, rounded to the nearest cent.

The exemption document (the "**Document**") only relates to the public offer of the Offer ADSs in the United Kingdom to the CureVac Shareholders on the terms of the Offer.

The Company's American Depositary Shares (the "**American Depositary Shares**", "**ADSs**" or "**BioNTech ADSs**") are, and the Offer ADSs will be, listed on the Nasdaq Global Select Market of the Nasdaq Stock Market LLC ("**Nasdaq**") under the symbol "BNTX", and have the International Securities Identification Number ("**ISIN**") US09075V1026 and the German Securities Identification Number (*Wertpapierkennnummer*, "**WKN**") A2PSR2.

The Document is dated October 20, 2025. This Document does not constitute a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 and its implementing legislation, as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 as amended (the "**Prospectus Regulation**") but does constitute an exemption document describing the transaction and its impact on BioNTech SE for the purposes of Article 1(4)(f) of the Prospectus Regulation. This Document has not been subject to the scrutiny and approval by the relevant competent authority in accordance with Article 20 of the Prospectus Regulation.

This summary should be read as an introduction to the Document. Any decision to invest in the Offer ADSs should be based on consideration of the Document as a whole by the investor. Investors could lose all or part of their invested capital. Civil liability attaches only to those persons who have tabled the summary including any translation thereof, but only where the summary is misleading, inaccurate, or inconsistent, when read together with the other parts of the Document, or where it does not provide, when read together with the other parts of the Document, key information in order to aid investors when considering whether to invest in the Offer ADSs.

1.2 Key Information on the Issuer

The following sections describe BioNTech SE, as the issuer of the newly issued ordinary registered shares represented by the Offer ADSs.

1.2.1 Who is the issuer of the securities?

Registration and Applicable Laws – The Company is incorporated as a European company (*Societas Europaea, SE*) in Germany and governed by German law, subject to the EU regulations on European companies, in particular the provisions of Council Regulation (EC) No. 2157/2001, as amended from time to time. The Company's domicile is Mainz, Germany, and it is registered with the commercial register (*Handelsregister*) of the local court (*Amtsgericht*) of Mainz, Germany, under number HRB 48720. The Company can be contacted at its business address: An der Goldgrube 12, 55131 Mainz, Germany, by telephone: +49 6131 9084-0, or via its website address: www.biontech.com. The Company's LEI is 894500UZJ5LG1F8J1U58.

Principal Activities – We believe we are a global next-generation immunotherapy company aiming to pioneer novel medicines against cancer, infectious diseases and other serious diseases. Since our founding in 2008, we have focused on harnessing the power of the immune system with the goal to address human diseases with unmet medical needs and major global health burdens. Our fully integrated model combines decades of research in immunology with a multi-technology innovation engine, Good Manufacturing Practice manufacturing, translational drug discovery, clinical development, commercial capabilities, computational medicine, data science and artificial intelligence, and machine learning, capabilities to discover, develop and commercialize our marketed product and product candidates. We have built a broad toolkit across multiple technology platforms, including a diverse range of potentially first-in-class therapeutic approaches. This includes investigational messenger ribonucleic acid, or mRNA immunotherapies, protein-based therapeutics (including targeted antibodies such as monoclonal, bispecific and antibody-drug conjugates) and cell therapies. We believe our multi-technology combination of platforms and product candidates positions us as pioneers in the field of individualized, patient-centric therapeutic approaches in oncology and infectious diseases. Our primary focus is oncology, where we endeavor to address the full continuum of cancer from early to late disease stages. The root causes of cancer treatment failure are cancer heterogeneity and interindividual variability. Driven by random sequential mutations, every patient's cancer is different and within one patient's tumor, every cell is different. Addressing these two challenges is the core of our strategy. To augment anti-tumor activity and to counteract resistance mechanisms, we seek to combine compounds with non-overlapping, potentially synergistic mechanisms of action. Our approach has generated a robust and diversified product candidate pipeline across a range of technologies in oncology and infectious disease, and has led to the approval of our first marketed product, *Comirnaty*.

Major Shareholders – AT Impf GmbH (the sole shareholder of which is ATHOS KG) holds 42.1% of the Company's ordinary shares and Medine GmbH (the sole shareholder of which is Prof. Ugur Sahin, M.D.) holds 16.7% of the shares or voting rights, with a further 0.5% of the shares held by Prof. Ugur Sahin, M.D. Pursuant to the deposit agreement governing the ADSs, the Company may instruct the ADSs' depositary to vote the shares that underly ADSs on uncontested agenda items for that portion of shares for which the depositary has not received specific voting instructions from the beneficial owners of ADSs. In prior shareholders' meetings of the Company, there were no contested agenda items, and AT Impf GmbH's (or, indirectly, ATHOS KG's) shareholding did not confer to it a majority of the votes cast at such meetings. Based solely on uncontested prior shareholders' meetings, if all Company-instructed votes were excluded from the voting tabulation, AT Impf GmbH (or, indirectly, ATHOS KG) would have voted a majority of the votes cast at such meetings and may therefore be considered to have *de facto* control over the Company.

Key Executive Directors – The members of the Company's management board (*Vorstand*) are Prof. Ugur Sahin, M.D. (Chief Executive Officer), Ramón Zapata-Gomez (Chief Financial Officer), Annemarie Hanekamp (Chief Commercial Officer), Sierk Poetting, Ph.D. (Chief Operating Officer), James Ryan, Ph.D. (Chief Legal Officer and Chief Business Officer) and Prof. Özlem Türeci, M.D. (Chief Medical Officer).

Auditors – The Company's auditor is EY GmbH & Co. KG Wirtschaftsprüfungsgesellschaft (formerly Ernst & Young GmbH Wirtschaftsprüfungsgesellschaft), Stuttgart, Germany, Cologne office, Börsenplatz 1, 50667 Cologne, Germany.

1.2.2 What is the key financial information regarding the issuer?

The unaudited interim condensed consolidated financial statements of the Company as of and for the three and six months ended June 30, 2025 were prepared by the Company in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board (IASB) applicable on interim financial reporting (IAS 34). The audited consolidated financial statements of the Company as of and for the year ended December 31, 2024 have been prepared by the Company in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board (IASB) and adopted by the European Union and the additional requirements of German commercial law pursuant to Section 315e para. 3 in conjunction with para. 1 of the German Commercial Code (*Handelsgesetzbuch*). The audited consolidated financial statements of the Company as of and for the years ended December 31, 2023 and December 31, 2022 have been prepared by the Company in accordance with International Financial Reporting Standards as adopted by the European Union and the additional requirements of German commercial law pursuant to Section 315e para. 3 in conjunction with para. 1 of the German Commercial Code (*Handelsgesetzbuch*).

In this summary of the Document, where financial information is presented as "audited" in tables, this means that it was taken from the audited consolidated financial statements referred to above. Where financial information is presented in tables as "unaudited", this indicates that the financial information has not been taken from the audited consolidated financial statements referred to above but has been taken either from the unaudited interim condensed consolidated financial statements referred to above, or from the Company's accounting records or internal management reporting system, or has been calculated based on figures from the above-mentioned sources. Financial information presented in parentheses or preceded by a "minus" sign denotes a negative amount.

1.2.2.1 Key financial information from the consolidated statements of profit or loss

	Six months ended June 30,		Years ended December 31,		
	2025	**2024**	**2024**	**2023**	**2022**
(in millions €, unless otherwise indicated)	**(unaudited)**		**(audited, unless otherwise indicated)**		
Revenues	443.6	316.3	2,751.1	3,819.0	17,310.6
Period-on-period revenue growth (in %) (unaudited)	40.2	—	*(28.0)*	*(77.9)*	—
Operating profit / (loss)	(1,035.2)	(1,473.4)	(1,314.3)	690.4	12,642.7
Net profit / (loss)	(802.4)	(1,122.9)	(665.3)	930.3	9,434.4
Earnings / (Loss) per share					
Basic earnings / (loss) per share	*(3.33)*	*(4.67)*	*(2.77)*	*3.87*	*38.78*
Diluted earnings */ (loss) per share*	*(3.33)*	*(4.67)*	*(2.77)*	*3.83*	*37.77*

1.2.2.2 Key financial information from the consolidated statements of financial position

	As of June 30,	As of December 31,		
	2025	**2024**	**2023**	**2022**
(in millions €)	**(unaudited)**	**(audited)**		
Total assets	21,637.6	22,529.7	23,006.3	23,279.1
Total equity	18,505.1	19,411.1	20,245.9	20,055.6

1.2.2.3 Key financial information from the consolidated statements of cash flows

	Six months ended June 30,		Years ended December 31,		
	2025	**2024**	**2024**	**2023**	**2022**
(in millions €)	**(unaudited)**		**(audited)**		
Net cash flows from / (used in) operating activities	(634.2)	1,309.9	207.7	5,371.4	13,577.4
Net cash flows from / (used in) investing activities	1,182.4	(2,545.8)	(2,081.2)	(6,954.5)	(35.3)
Net cash flows used in financing activities	(27.1)	(30.7)	(45.9)	(778.6)	(1,419.3)
Cash and cash equivalents as of the end of the period	10,269.5	10,376.7	9,761.9	11,663.7	13,875.1

1.2.3 What are the key risks that are specific to the issuer?

An investment in the Offer ADSs is subject to a number of risks. The following risks are key risks specific to us:

- Demand for our COVID-19 vaccine, though difficult to predict, is expected to continue to decrease in the near future. Changing market dynamics will impact our revenues, which currently depends heavily on sales of our COVID-19 vaccine. Uncertainty in the demand for our COVID-19 vaccine and difficulties in targeting appropriate supply of our COVID-19 vaccines have in the past resulted, and may in the future result, in significant inventory write-downs and cancellations of contract manufacturing orders. Our business and financial condition could be materially affected by lowered COVID-19 vaccine revenues resulting from factors affecting demand for our COVID-19 vaccine, or by production and supply chain difficulties.
- The successful commercialization of our product candidates will depend in part on the extent to which governmental authorities, private health insurers and other third-party payors provide coverage and adequate reimbursement levels and implement pricing policies favorable to our product candidates. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, and/or delayed payments from government authorities could limit our ability to market those products and decrease our ability to generate revenues.
- If we are unable to continue to increase our marketing and sales capabilities on our own or through third parties, we may not be able to market and sell our product candidates effectively in the United States and other jurisdictions, if approved, or generate sufficient product sales revenue.
- Our operating results may fluctuate significantly, which makes our future operating results difficult to predict. If our operating results fall below expectations, the price of the ADSs representing our ordinary shares could decline.
- We may encounter difficulties in developing and expanding our company and managing such development and expansion, which could disrupt our operations.
- Our business is dependent on the successful development, regulatory approval and commercialization of product candidates based on our technology platforms. If we and our collaborators are unable to obtain approval for and effectively commercialize our product candidates for the treatment of patients in their intended indications, our business would be significantly harmed.
- Clinical development involves a lengthy and expensive process with an uncertain outcome, and delays can occur for a variety of reasons outside of our control. Clinical trials of our product candidates may be delayed, certain programs may never advance in the clinic or may be more costly to conduct than we anticipate, and we may have difficulty recruiting patients to participate in clinical trials, any of which can affect our ability to fund our company and would have a material adverse impact on our business.
- We and our collaborators or other contractors or consultants depend on information technology systems, and any failure of these systems could harm our business. Security breaches, loss of data and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business, results of operations and financial condition.
- Our COVID-19 vaccine and product candidates are based on novel technologies and they may be complex and difficult to manufacture. We may encounter difficulties in manufacturing, product release, shelf life, testing, storage, supply chain management or shipping. If we or any of the third-party manufacturers we work with encounter such difficulties, our ability to supply materials for clinical trials or any approved product could be delayed or stopped.
- We rely on third parties in the conduct of significant aspects of our preclinical studies and clinical trials and intend to rely on third parties in the conduct of future clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or fail to meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates.
- We and our collaborators rely on third parties to manufacture certain of our clinical product supplies, and we may have to rely on third parties to produce and process our product candidates, if approved.
- If our efforts to obtain, maintain, protect, defend and/or enforce the intellectual property related to our COVID-19 vaccine or our product candidates and technologies are not adequate, we may not be able to compete effectively in our market.
- The United States', the European or other comparable regulatory authorities may disagree with our regulatory plan and we may fail to obtain regulatory approval of our product candidates.
- Our COVID-19 vaccine and any other product candidates for which we receive approval or emergency use authorization are subject to continuing regulatory oversight, and we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. We may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products or product candidates.

1.3 Key Information on the Securities

1.3.1 What are the main features of the securities?

The Document relates to the Offer by the Company of 15,061,575 Offer ADSs in exchange for all issued CureVac Shares.

Number and Nature of ADSs.	As of October 17, 2025, 101,103,358 ADSs were issued. Each ADSs represents one (1) ordinary registered share with no par value (*auf den Namen lautende Stückaktie*) of the Company, as described in section "*Underlying Shares*" below. The Offer ADSs will be ADSs of the same class. The Offer ADS will be registered and delivered by The Bank of New York Mellon as depositary. The Bank of New York Mellon is a banking corporation organized pursuant to the laws of the State of New York, whose registered office is at 240 Greenwich St, NY, NY 10286, United States of America (the "**United States**" or "**U.S.**"). The Bank of New York Mellon's LEI is WFLLPEPC7FZXENRZV188.
ISIN, and Denomination of the ADSs	The ADSs' ISIN is US09075V1026 and their Nasdaq Trading Symbol is "BNTX". The American Depositary Shares are denominated in U.S. dollars.
Rights Attached to the ADSs	The deposit agreement and any receipts created thereunder evidencing the American Depositary Shares are governed by the laws of the State of New York, United States. The deposit agreement provides for the following main features of the rights attached to the ADSs:
Voting Rights	ADS holders may instruct the depositary how to vote the number of deposited shares their ADSs represent. If the Company requests the depositary to solicit a holder's voting instructions (and the Company is not required to do so), the depositary will notify the holder of a shareholders' meeting and send or make voting materials available to it. Those materials will describe the matters to be voted on and explain how ADS holders may instruct the depositary how to vote. For instructions to be valid, they must reach the depositary by a date set by the depositary. The depositary will try, as far as practical, subject to the laws of the State of New York and the

	provisions of the Company's articles of association or similar documents, to vote or to have its agents vote the shares or other deposited securities as instructed by ADS holders. If the Company does not request the depositary to solicit a holder's voting instructions, a holder can still send voting instructions, and, in that case, the depositary may try to vote as instructed, but it is not required to do so. Except by instructing the depositary as described above, an ADS holder will not be able to exercise voting rights unless it surrenders its ADSs and withdraws the underlying ordinary shares. However, an ADS holder may not know about the shareholders' meeting enough in advance to withdraw the underlying ordinary shares.
Deposit and Withdrawal.....	The depositary will deliver ADSs if the ADS holder or its broker deposits shares or evidence of rights to receive shares with the custodian. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or stock transfer taxes or fees, the depositary will register the appropriate number of ADSs in the names the holder requests and will deliver the ADSs to or upon the order of the person or persons that made the deposit. An ADS holder may surrender its ADSs to the depositary for the purpose of withdrawal. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or stock transfer taxes or fees, the depositary will deliver the underlying ordinary shares and any other deposited securities underlying the ADSs to the ADS holder or a person the ADS holder designates at the office of the custodian. Or, at the ADS holder's request, risk and expense, the depositary will deliver the deposited securities at its office, if feasible. However, the depositary is not required to accept surrender of ADSs to the extent it would require delivery of a fraction of a deposited share or other security. The depositary may charge the ADS holder a fee and its expenses for instructing the custodian regarding delivery of deposited securities.
Dividend Rights and Other Distributions.....	The depositary has agreed to pay or distribute to ADS holders the cash dividends or other distributions it or the custodian receives on shares or other deposited securities, upon payment or deduction of its fees and expenses. ADS holders will receive these distributions in proportion to the number of shares their ADSs represent.
Underlying Shares.....	The shares underlying the ADSs are ordinary registered shares with no par value (*auf den Namen lautende Stückaktien*) with a notional amount attributable to each ordinary share of €1.00 in the Company's share capital and carry full dividend rights as from January 1, 2025, provided that the relevant shares shall carry full dividend rights as from January 1, 2026 if such new ordinary shares are issued after the Company's shareholders' meeting has resolved on the distribution of the accumulated profit for the financial year ended December 31, 2025. Their ISIN is: DE000A0V9BC4. The ordinary shares are denominated in euro. The ordinary shares resulting from the share capital increases which shall be implemented to issue the Company's shares that will underly the Offer ADSs shall be shares of the same class. Each of the ordinary registered shares of the Company shall entitle the shareholder to one vote at the Company's shareholders' meeting. The ordinary shares are subordinated to all other securities and claims in case of an insolvency of the Company. All shares entitle the shareholders to a share of any distributable liquidation proceeds or insolvency surpluses at the ratio of their proportion in the share capital. The shares are freely transferable in accordance with the legal requirements for registered shares (*Namensaktien*).
***Transferability*.....**	American Depositary Shares evidenced by an American Depositary Receipt ("**ADR**"), when the ADR is properly endorsed or accompanied by proper instruments of transfer, are transferable as certificated registered securities under the laws of the State of New York. American Depositary Shares not evidenced by ADRs are transferable as uncertificated registered securities under the laws of the State of New York.
***Dividend Policy*...**	We do not anticipate paying any cash dividends on our ordinary shares in the foreseeable future. We intend to retain all available funds and any future earnings to fund the development and expansion of our business.

1.3.2 Where will the securities be traded?

The Offer ADSs will be listed on the Nasdaq Global Select Market under the symbol "BNTX". Application to trading of the Company's ordinary shares to any trading venue is not planned.

1.3.3 What are the key risks that are specific to the securities?

The following risk is a key risk specific to the ADSs:

- We have experienced and may continue to experience significant volatility in the market price of the BioNTech ADSs.

1.4 Key Information on the Offer of Securities to the Public and the Admission to Trading on a Regulated Market

1.4.1 Under which conditions and timetable can I invest in this security?

Under the Offer, the Company offers 15,061,575 Offer ADSs in exchange for all issued CureVac Shares. In exchange for each tendered CureVac Share, the Company offers a number of Offer ADSs determined by multiplying the number of tendered CureVac Shares with the Exchange Ratio, taken to five decimals. The Exchange Ratio is determined by dividing $5.4641 by the BioNTech ADS VWAP. The BioNTech ADS VWAP in turn is determined as the volume-weighted average of the price per BioNTech ADS, taken to four decimal places, over the period of ten consecutive trading days ending on, and including, the fifth trading day immediately preceding the time on which the initial Offer expires (as it may be extended), and is subject to the following collar adjustment: In the event the BioNTech ADS VWAP is greater than or equal to $126.55, the Exchange Ratio will be 0.04318 and in the event the BioNTech ADS VWAP is less than or equal to $84.37, the Exchange Ratio will be 0.06476. The resulting number of Offer ADSs to be received is referred to as the Offer Consideration. From June 12, 2025, when BioNTech and CureVac announced the execution of the Purchase Agreement, through October 17, 2025, the BioNTech ADS VWAP was not greater than or equal to $126.55 or less than or equal to $84.37. Accordingly, the Offer Consideration at all times during that period represented a market value of $5.4641. However, were the BioNTech ADS VWAP to, for example, drop to $80 or go above $130 on the applicable calculation date, the market value of the Offer Consideration could be greater than or less than, respectively, $5.4641. Accordingly, as of the date of the Document, CureVac Shareholders will not know, or be able to calculate, the exact market value of the consideration that they will receive upon closing of the Offer or completion of the post-offer reorganization. During the Offer, an indicative Exchange Ratio (calculated in the manner described in the Document) will be available at http://www.envisionreports.com/CureVacOffer, beginning on October 22, 2025. The Company will only deliver whole Offer ADSs. For any fractional Offer ADSs, the tendering CureVac Shareholder will instead receive an amount in cash, without interest and less any applicable tax withholding equal to the product of (i) the fractional Offer ADS interest such shareholder otherwise would be entitled to and (ii) the BioNTech ADS VWAP, rounded to the nearest cent.

The Offer is made in accordance with the terms of the Purchase Agreement and applicable rules and regulations. The Offer consists of (i) a public offer in the United States registered under the United States Securities Act of 1933, as amended pursuant to a registration

statement on Form F-4 filed with the United States Securities and Exchange Commission ("**SEC**"), (ii) a public offer in Germany, Austria, France, Italy, the Netherlands and Spain and (iii) a public offer in the United Kingdom.

1.4.1.1 Procedures for tendering

Upon commencement of the Offer, BioNTech will mail, or cause to be mailed, the offer to exchange, together with the letter of transmittal, to all CureVac Shareholders, in accordance with Rule 14d-4 under the U.S. Securities Exchange Act of 1934, as amended (the "**Exchange Act**"). If CureVac Shares are held through a broker, dealer, commercial bank, trust company, or other nominee, such person may receive such materials and may relay them to the shareholder in accordance with the arrangements governing that relationship.

- If CureVac Shares are directly registered in the shareholder's own name in CureVac's shareholders register, including if the shareholder is a record holder and holds shares in book-entry form on the books of CureVac's transfer agent, the following must be received by Computershare Trust Company, N.A. (the "**Exchange Agent**") prior to the Expiration Time: (i) the letter of transmittal, properly completed and duly executed, and (ii) any other documents required by the letter of transmittal.
- If CureVac Shares are held in "street" name and are being tendered by book-entry transfer into an account maintained at The Depository Trust Company ("**DTC**"), the following must be received by the Exchange Agent prior to the Expiration Time: (i) the letter of transmittal, properly completed and duly executed, or an agent's message; (ii) a book-entry confirmation from DTC; and (iii) any other required documents.
- If CureVac Shareholders hold their shares through a broker, dealer, commercial bank, trust company, or other nominee, they must contact their broker, dealer, commercial bank, trust company, or other nominee and give instructions that their shares be tendered.

The term "agent's message" means a message transmitted by DTC to, and received by, the Exchange Agent and forming a part of a book-entry confirmation, which states that DTC has received an express acknowledgment from the DTC participant tendering the CureVac Shares that are the subject of such book-entry confirmation, that such participant has received and agrees to be bound by the terms of the letter of transmittal and that the Company may enforce that agreement against such participant.

The Exchange Agent will establish an account with respect to the CureVac Shares at DTC for purposes of the Offer, and any eligible institution that is a participant in DTC may make book-entry delivery of the CureVac Shares by causing DTC to transfer such shares into the Exchange Agent's account at DTC in accordance with DTC's procedure for the transfer. Delivery of documents to DTC does not constitute delivery to the Exchange Agent.

Trustees, executors, administrators, guardians, attorneys-in-fact, officers of corporations, or others acting in a fiduciary or representative capacity who sign a letter of transmittal or any stock powers must indicate the capacity in which they are signing and must submit evidence of their power to act in that capacity unless waived by the Company.

The method of delivery of CureVac Shares and all other required documents, including delivery through DTC, is at the option and risk of the tendering CureVac Shareholder, and delivery will be deemed made only when actually received by the Exchange Agent.

1.4.1.2 Key Terms of the Offer

Initial Offer and Extension	The Offer will commence on October 21, 2025, 4:00 p.m. (New York City time), and will initially remain open until 9:00 a.m. (New York City time) on December 3, 2025. The Company may extend the initial Offer to such other date and time as may be agreed in writing by the Company and CureVac. The Company will also extend the initial Offer for any minimum period as required by the SEC or Nasdaq. Furthermore, if, at the scheduled Expiration Time, any of the offer conditions have not been satisfied or waived by the Company, the Company must extend the Offer on one or more occasions in consecutive periods of up to 10 business days each (or such other duration as may be agreed to by the Company and CureVac) in order to permit the satisfaction of such offer conditions. The Company may extend the Offer for up to 20 business days if it is not reasonably likely that, within such 10-business day extension period, a required antitrust approval will be obtained, or deemed to be obtained, and/or a legal restraint will not be removed. The Company is not required to extend the Offer on more than four occasions in consecutive periods of up to 10 business days each if the sole unsatisfied condition is the Minimum Condition (as defined below). The Company is not required to extend the Offer beyond March 12, 2026. If all conditions to the Offer, other than the required antitrust approvals, are satisfied or capable of being satisfied, the outside date of March 12, 2026 will be extended for up to two additional 90-day periods. Under the Purchase Agreement, if any of the resolutions of CureVac that are a condition to the closing of the Offer are not approved and adopted at a shareholder meeting, a subsequent shareholder meeting may be held to obtain the approval of the remaining outstanding resolutions.
Subsequent Offering Period	Following the Expiration Time and subject to the satisfaction or waiver of the offer conditions, the Company will accept for exchange any validly tendered CureVac Shares (such time, the "**Acceptance Time**"). Following the Acceptance Time, the Company will provide for a subsequent offering period in accordance with Rule 14d-11 promulgated under the Exchange Act of not less than 10 Business Days (calculated in accordance with Rule 14d-1(g)(3) promulgated under the Exchange Act) (the "**Subsequent Offering Period**").
Offer Conditions	The Company's obligation to acquire CureVac Shares validly tendered and not properly withdrawn pursuant to the Offer is subject to the satisfaction or waiver of various closing conditions, which are set forth in the Purchase Agreement. The offer conditions include, in addition to customary conditions: (i) CureVac Shares representing at least 80% of CureVac's share capital immediately prior to the Expiration Time have been validly tendered and not properly withdrawn immediately prior to the Expiration Time (the "**Minimum Condition**"); provided that the Company may reduce the Minimum Condition to 75% under certain circumstances; (ii) necessary antitrust and other regulatory approvals shall have been received, or be deemed to have been received and be in full force and effect; (iii) there having not been any fact, change, event, development, occurrence, or effect that, individually or in the aggregate, materially adversely affects, or would reasonably be expected to materially adversely affect, the business, assets, results of operations or condition of the Company and/or CureVac and their respective subsidiaries, taken as a whole (subject to certain exceptions); and (iv) the extraordinary general meeting of CureVac has adopted resolutions providing (a) for the appointment of the Company designees to CureVac's management board and supervisory board to replace the resigning members effective upon the closing of the Offer; (b) the approval of a post-offer reorganization; and (v) the Purchase Agreement not having been terminated in accordance with its terms.
Dilution	Based on the net asset value attributable to owners of the parent (net book value) in the consolidated statement of position of the Company as of June 30, 2025, 240,455,450 outstanding ordinary shares in the Company (i.e., excluding treasury shares) as of the date of the Document, the (accretion) / dilution for new shareholders of the Company will be between approximately (6.0)% and approximately 38.2% and the accretion / (dilution) to existing shareholders of the Company will be between approximately (0.5)% and approximately 1.5%, in each case depending on the final Exchange Ratio. The shareholding percentage of BioNTech shareholders will decrease by between approximately 5.9% and approximately 4.0% (calculated on a basis excluding treasury shares), depending on the final Exchange Ratio.
Total Expenses	The costs related to the Offer are expected to total approximately €17.5 million.

Expenses Charged to Investors	CureVac Shareholders which are the record owner of their CureVac Shares and tender their shares directly to the Exchange Agent will not have to pay brokerage fees, commissions, or similar expenses. If CureVac Shares are owned through a broker, dealer, commercial bank, trust company, or other nominee and the CureVac Shareholder's broker, dealer, commercial bank, trust company, or other nominee tenders the CureVac Shares on such shareholders behalf, the broker, dealer, commercial bank, trust company, or nominee may charge a fee for doing so. CureVac Shareholders should consult their broker, dealer, commercial bank, trust company, or nominee to determine whether any charges will apply.

1.4.1.3 Anticipated timetable

The expected timetable for the Offer, which may be extended or shortened and remains subject to change, is as follows, assuming that the initial Offer will not be extended and that the conditions to closing of the Offer will be satisfied or waived and a Subsequent Offering Period of 10 business days applies:

October 20, 2025	Publication of the Document on the website of BioNTech SE (https://investors.biontech.de under the "Investors — CureVac Tender Offer — CureVac Tender Offer Materials for UK Investors" section).
October 21, 2025, 4:00 p.m. (New York City time)	Commencement of the initial Offer.
November 25, 2025	Determination of the final Exchange Ratio.
By no later than November 26, 2025, 9:00 a.m. (New York City time)	Publication of the final Exchange Ratio by press release.
December 3, 2025, 9:00 a.m. (New York City time)	End of the initial Offer (Expiration Time).
By December 3, 2025, 6:00 p.m. (New York City time)	Occurrence of the Acceptance Time and publication of the result of the initial Offer on the same day.
December 4, 2025	Commencement of Subsequent Offering Period.
On or about December 4, 2025	Resolutions on the first share capital increase and the related share issuance for the ordinary shares that will underly the Offer ADSs for CureVac Shares to be acquired from CureVac Shareholders having tendered in the initial Offer.
On or about December 15, 2025	Registration of the Share Capital Increase with the Company's commercial register, delivery of the Offer ADSs to the Exchange Agent. The BioNTech ADSs are listed on Nasdaq as a class, and the Offer ADSs will be tradable upon their delivery.
On or about December 17, 2025	Onward delivery of the Offer ADSs and payment of any cash in lieu of fractional Offer ADSs to CureVac Shareholders having validly tendered CureVac Shares in the initial Offer.
December 18, 2025, 12:01 a.m. (New York City time)	End of Subsequent Offering Period and publication of the result of the Subsequent Offering Period on the same day.
On or about December 19, 2025	Resolutions on the second share capital increase and the related share issuance for the ordinary shares that will underly the Offer ADSs for CureVac Shares to be acquired from CureVac Shareholders having tendered in the Subsequent Offering Period.
On or about January 2, 2026	Registration of the Share Capital Increase with the Company's commercial register and delivery of the Offer ADSs to the Exchange Agent. The BioNTech ADSs are listed on Nasdaq as a class, and the Offer ADSs will be tradable upon their delivery.
On or about January 6, 2026	Onward delivery of the Offer ADSs and payment of any cash in lieu of fractional Offer ADSs to CureVac Shareholders having validly tendered CureVac Shares in the Subsequent Offering Period.

1.4.2 Who is the offeror and/or the person asking for admission to trading?

Offeror	The Company is the offeror of the Offer ADSs.
Admission to Trading	The Offer ADSs will be listed on the Nasdaq Global Select Market. There will be no admission to trading on any other regulated market within the meaning of Article 2 point (j) of the Prospectus Regulation.

1.4.3 Why is this Document being produced?

Reasons for the Offer	The Company's boards believe that the acquisition of CureVac will have significant potential strategic benefits, including that the acquisition will support the global execution of the BioNTech's strategy to develop, manufacture, and commercialize mRNA-based medicines in oncology as well as expand BioNTech's capabilities to research, develop, manufacture, and commercialize mRNA-based medicines as a pan-tumor technology platform in oncology. As a result of the transaction, BioNTech will obtain complementary capabilities and proprietary technologies in target discovery, production, mRNA design, and delivery formulations. The transaction complements BioNTech's recent acquisitions in its other key pillars in oncology, including immunomodulators like bispecific antibodies and targeted therapies like antibody-drug conjugates.
Net Proceeds; Use of Proceeds	The Company intends to acquire all issued CureVac Shares under the Offer. The Company will not receive any proceeds from the Offer.
Tender and Support Agreements	Shareholders of CureVac representing approximately 57% of CureVac Shares, namely dievini Hopp BioTech holding GmbH & Co. KG and certain of its affiliates, Kreditanstalt für Wiederaufbau (KfW), Glaxo Group Limited and all members of CureVac's boards have entered into tender and support agreements pursuant to which they have agreed to (i) accept the Offer in respect of CureVac Shares held by them and (ii) vote in favor of all resolutions proposed by CureVac at its extraordinary general meetings resolving, among other things, on the post-offer reorganization and against certain proposals incompatible with the transactions contemplated by the Purchase Agreement, subject to the conditions and in accordance with the terms set forth therein. Other than these commitments, the Offer is not subject to any firm commitment.
Material Conflicts of Interest	There are no material conflicts of interest with respect to the Offer.